SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Revenue showed a marginal decline at Rs. 9736.30 millions. For the quarter ended September 2025, as compared to corresponding quarter of last year.Net profit showed a marginal rise at Rs. 2550.00 millions for the quarter ended September 2025, as compared to corresponding quarter of last year.Operating Profit saw a handsome growth to 3659.50 millions from 3511.40 millions in the quarter ended September 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202509 202409 % Var 202509 202409 % Var 202503 202403 % Var
Sales 9736.30 10000.50 -2.64 17784.60 18110.50 -1.80 37234.90 34072.50 9.28
Other Income 312.70 321.90 -2.86 750.30 680.40 10.27 1425.60 1234.80 15.45
PBIDT 3659.50 3511.40 4.22 6604.60 6164.10 7.15 13118.50 10241.30 28.09
Interest 5.10 2.70 88.89 9.30 6.40 45.31 13.10 18.00 -27.22
PBDT 3680.80 3555.60 3.52 6621.70 6204.60 6.72 13152.30 8787.20 49.68
Depreciation 174.30 168.60 3.38 329.50 332.70 -0.96 667.90 696.80 -4.15
PBT 3506.50 3387.00 3.53 6292.20 5871.90 7.16 12484.40 8090.40 54.31
TAX 956.50 900.10 6.27 1695.20 1568.50 8.08 3293.80 2243.50 46.82
Deferred Tax 4.40 -74.50 -105.91 4.60 -39.40 -111.68 62.00 -113.60 -154.58
PAT 2550.00 2486.90 2.54 4597.00 4303.40 6.82 9190.60 5846.90 57.19
Equity 1694.10 1694.10 0.00 1694.10 1694.10 0.00 1694.10 1694.10 0.00
PBIDTM(%) 37.59 35.11 7.05 37.14 34.04 9.11 35.23 30.06 17.21

Glaxosmithkline Phar Share Price

2393.25 32.95 (1.40%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×